CAR-T therapy market seen reaching $6.08 billion by 2030

The Business Research Company projects the CAR-T therapy market will rise from $2.98 billion in 2025 to $3.45 billion in 2026, then grow to $6.08 billion by 2030. The report points to rising cancer cases, broader approvals, and expanding manufacturing capacity as major drivers.

Why it matters: - CAR-T therapy is gaining momentum as cancer treatment expands beyond early adopters and more patients look for personalized immunotherapy. - The market’s projected rise to $6.08 billion by 2030 signals continued commercial opportunity for drugmakers, manufacturers, and research partners. - Faster growth could improve access if companies succeed in lowering treatment costs and scaling production.

What happened: - The Business Research Company released a CAR-T Therapy Market Report 2026 covering market size, trends, and global forecasts through 2035. - The report pegs the market at $2.98 billion in 2025 and $3.45 billion in 2026, a 15.9% increase. - The company forecasts the market will reach $6.08 billion by 2030, implying a 15.2% CAGR. - North America led the CAR-T therapy market in 2025, with Western Europe ranked second. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The company also published a free sample report and a full report online: Download the sample report and View the full report.

The details: - CAR-T therapy uses a patient’s T-cells, which are extracted from blood, genetically modified with a chimeric antigen receptor, and infused back into the body to attack cancer cells. - The CAR protein binds to a specific antigen on cancer cells, helping the engineered T-cells identify and destroy malignant cells. - Historical market growth has been shaped by limited availability of personalized immunotherapy, high early treatment costs, hospital-based cell processing systems, emerging regulation, and low patient awareness. - Future growth is expected to come from advances in T-cell engineering, higher oncology investment, expanded commercial manufacturing, broader approvals, and deeper collaboration between biopharma companies and academic institutions. - Key trends include wider use in hematologic cancers, antigen-specific CAR-T development, more combination therapies, more clinical trials, and efforts to reduce costs and improve access. - The report says CAR-T therapy is a personalized approach that leverages the body’s immune system to fight cancer.

Between the lines: - The market forecast suggests the field is moving from niche innovation toward broader clinical and commercial adoption. - Rising cancer incidence is reinforcing demand for advanced treatments, which can support pricing power but also intensify pressure to improve access. - The focus on manufacturing capacity and cost reduction points to the main bottlenecks that could limit growth if the industry cannot scale efficiently. - In Australia, cancer cases rose from 160,570 in 2022 to 164,694 in 2023, according to Australian Institute of Health and Welfare data cited in the report.

What's next: - The market’s next phase will likely hinge on expanded approvals, more clinical trial data, and whether manufacturers can lower costs without slowing innovation. - Companies working on CAR-T therapies will likely continue targeting hematologic cancers while pushing into broader applications. - The report’s forecasting tools and updated market analysis are positioned to guide investment, partnership, and expansion decisions.

The bottom line: - CAR-T therapy is moving deeper into mainstream oncology, and the market outlook points to sustained growth if the industry can solve access, manufacturing, and cost challenges.